{"id":"flupentixol","rwe":[{"pmid":"41249411","year":"2025","title":"Evaluating the ciprofloxacin potentiation efficacy of repurposed drug flupentixol through efflux pump inhibition of pathogenic bacteria.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41210421","year":"2025","title":"Bilateral temporomandibular joint dislocation secondary to acute dystonia induced by antipsychotic depot injection: a case report.","finding":"","journal":"AME case reports","studyType":"Clinical Study"},{"pmid":"41063663","year":"2025","title":"Osmotic Demyelination Syndrome in a Patient With Schizophrenia: A Case Report.","finding":"","journal":"Neuropsychopharmacology reports","studyType":"Clinical Study"},{"pmid":"41011127","year":"2025","title":"Use of TLC and Computational Methods to Determine Lipophilicity Parameters of Selected Neuroleptics: Comparison of Experimental and Theoretical Studies.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"40936465","year":"2025","title":"Correlations between receptor occupancy change and mental state in patients using long-acting injectable antipsychotics: MIDILIA pilot study.","finding":"","journal":"BJPsych open","studyType":"Clinical Study"}],"tags":[{"label":"High Risk QT Prolonging Agents","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"DRD3","category":"gene"},{"label":"DRD2","category":"gene"},{"label":"N05AF01","category":"atc"},{"label":"Active","category":"status"},{"label":"Schizophrenia","category":"indication"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":1491.369,"date":"","count":256,"signal":"Blood prolactin abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 256 times (LLR=1491)"},{"llr":1486.965,"date":"","count":257,"signal":"Anosognosia","source":"DrugCentral FAERS","actionTaken":"Reported 257 times (LLR=1487)"},{"llr":1393.285,"date":"","count":256,"signal":"Disturbance in social behaviour","source":"DrugCentral FAERS","actionTaken":"Reported 256 times (LLR=1393)"},{"llr":1251.15,"date":"","count":259,"signal":"Sexual dysfunction","source":"DrugCentral FAERS","actionTaken":"Reported 259 times (LLR=1251)"},{"llr":1211.163,"date":"","count":256,"signal":"Metabolic disorder","source":"DrugCentral FAERS","actionTaken":"Reported 256 times (LLR=1211)"},{"llr":1173.48,"date":"","count":391,"signal":"Suicide attempt","source":"DrugCentral FAERS","actionTaken":"Reported 391 times (LLR=1173)"},{"llr":1119.975,"date":"","count":242,"signal":"Personality change","source":"DrugCentral FAERS","actionTaken":"Reported 242 times (LLR=1120)"},{"llr":943.306,"date":"","count":242,"signal":"Dystonia","source":"DrugCentral FAERS","actionTaken":"Reported 242 times (LLR=943)"},{"llr":904.553,"date":"","count":278,"signal":"Dyskinesia","source":"DrugCentral FAERS","actionTaken":"Reported 278 times (LLR=905)"},{"llr":817.987,"date":"","count":266,"signal":"Sedation","source":"DrugCentral FAERS","actionTaken":"Reported 266 times (LLR=818)"},{"llr":578.787,"date":"","count":260,"signal":"Blood glucose increased","source":"DrugCentral FAERS","actionTaken":"Reported 260 times (LLR=579)"},{"llr":552.229,"date":"","count":107,"signal":"Antipsychotic drug level below therapeutic","source":"DrugCentral FAERS","actionTaken":"Reported 107 times (LLR=552)"},{"llr":511.911,"date":"","count":107,"signal":"Disinhibition","source":"DrugCentral FAERS","actionTaken":"Reported 107 times (LLR=512)"},{"llr":504.202,"date":"","count":104,"signal":"Therapeutic product effect variable","source":"DrugCentral FAERS","actionTaken":"Reported 104 times (LLR=504)"},{"llr":497.499,"date":"","count":121,"signal":"Obsessive-compulsive disorder","source":"DrugCentral FAERS","actionTaken":"Reported 121 times (LLR=497)"}],"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Highest Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"}],"commonSideEffects":[{"effect":"Blood prolactin abnormal","drugRate":"LLR 1491","severity":"serious"},{"effect":"Anosognosia","drugRate":"LLR 1487","severity":"serious"},{"effect":"Disturbance in social behaviour","drugRate":"LLR 1393","severity":"serious"},{"effect":"Sexual dysfunction","drugRate":"LLR 1251","severity":"serious"},{"effect":"Metabolic disorder","drugRate":"LLR 1211","severity":"serious"},{"effect":"Suicide attempt","drugRate":"LLR 1173","severity":"serious"},{"effect":"Personality change","drugRate":"LLR 1120","severity":"serious"},{"effect":"Dystonia","drugRate":"LLR 943","severity":"serious"},{"effect":"Dyskinesia","drugRate":"LLR 905","severity":"serious"},{"effect":"Sedation","drugRate":"LLR 818","severity":"serious"},{"effect":"Blood glucose increased","drugRate":"LLR 579","severity":"serious"},{"effect":"Antipsychotic drug level below therapeutic","drugRate":"LLR 552","severity":"serious"},{"effect":"Disinhibition","drugRate":"LLR 512","severity":"serious"},{"effect":"Therapeutic product effect variable","drugRate":"LLR 504","severity":"serious"},{"effect":"Obsessive-compulsive disorder","drugRate":"LLR 497","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:58:39.577751","allNames":"fluanxol","offLabel":[],"synonyms":["flupentixol hydrochloride","flupenthixol","fluanxol","flupentixol","fluxanxol","flupentixol dihydrochloride","N-7009","flupentixol HCl"],"timeline":[{"date":"1964-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1964-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Fluanxol","ecosystem":[{"indication":"Schizophrenia","otherDrugs":[{"name":"aripiprazole","slug":"aripiprazole","company":"Otsuka"},{"name":"aripiprazole lauroxil","slug":"aripiprazole-lauroxil","company":"Alkermes"},{"name":"asenapine","slug":"asenapine","company":"Forest Labs Inc"},{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"}],"globalPrevalence":24000000}],"mechanism":{"target":"Histamine H1 receptor","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor","isPrimary":true,"activityType":"Ki","activityValue":9.066},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"},{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"DRD1","source":"DrugCentral","target":"D(1A) dopamine receptor","protein":"D(1A) dopamine receptor"},{"gene":"DRD5","source":"DrugCentral","target":"D(1B) dopamine receptor","protein":"D(1B) dopamine receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"KCNK2","source":"DrugCentral","target":"Potassium channel subfamily K member 2","protein":"Potassium channel subfamily K member 2"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"}],"modality":"Small Molecule","drugClass":"High Risk QT Prolonging Agents","explanation":"Think of histamine like a messenger in your brain that can make you feel anxious or excited. Flupentixol blocks this messenger, helping to calm down overactive brain signals that can contribute to schizophrenia symptoms. By reducing these signals, flupentixol can help improve mood and cognitive function.","oneSentence":"Flupentixol works by blocking the histamine H1 receptor, which helps regulate various physiological processes including mood and cognition.","technicalDetail":"Flupentixol acts as a competitive antagonist at the histamine H1 receptor, inhibiting the binding of histamine and reducing the downstream effects of histamine signaling, which is thought to contribute to its therapeutic effects in schizophrenia."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1211","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLUPENTIXOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUPENTIXOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:35:29.367950","biosimilars":[],"competitors":[{"drugName":"chlorprothixene","drugSlug":"chlorprothixene","fdaApproval":"1967-06-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"thiothixene","drugSlug":"thiothixene","fdaApproval":"1967-07-24","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"flupentixol","indications":{"approved":[{"name":"Schizophrenia","source":"DrugCentral","snomedId":58214004,"regulator":"FDA","usPrevalence":2800000,"globalPrevalence":24000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"}],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget","pubmed(446)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chlorprothixene","brandName":"chlorprothixene","genericName":"chlorprothixene","approvalYear":"1967","relationship":"same-class"},{"drugId":"thiothixene","brandName":"thiothixene","genericName":"thiothixene","approvalYear":"1967","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05766007","phase":"","title":"Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-08-01","conditions":["Schizophrenia","Psychosis","Mania","Pregnancy","Drug Exposure in Utero","Drug Exposure Via Breast Milk","Antipsychotic Agents","Breastfeeding"],"enrollment":125,"completionDate":"2026-06-30"},{"nctId":"NCT06945237","phase":"NA","title":"Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2025-04-24","conditions":["Gastroesophageal Reflux Disease"],"enrollment":164,"completionDate":"2025-10-30"},{"nctId":"NCT03513185","phase":"","title":"Assessment of SSD in Outpatients Using SSS-CN","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2017-09-01","conditions":["Somatization Disorder"],"enrollment":1863,"completionDate":"2021-12-30"},{"nctId":"NCT06756139","phase":"NA","title":"Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia","status":"RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-11-01","conditions":["Functional Dyspepsia","Self-help Mobile Cognitive Behavioral Therapy","Antipsychotic Drug"],"enrollment":88,"completionDate":"2025-11-01"},{"nctId":"NCT06931223","phase":"NA","title":"Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-10","conditions":["Functioanl Dyspepsia"],"enrollment":200,"completionDate":"2025-09-10"},{"nctId":"NCT06927375","phase":"PHASE4","title":"A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2024-12-12","conditions":["Thyroid-Associated Ophthalmopathy"],"enrollment":60,"completionDate":"2026-03-12"},{"nctId":"NCT03472651","phase":"PHASE1","title":"Bioequivalence Study to Compare Two Formulations of Deanxit®","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-05-07","conditions":["Healthy"],"enrollment":60,"completionDate":"2018-06-28"},{"nctId":"NCT05099913","phase":"NA","title":"The Role of Neuromodulators in Refractory Functional Dyspepsia","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-08-01","conditions":["Dyspepsia","Functional Gastrointestinal Disorders","Antidepressant Discontinuation Syndrome","Antidepressant Drug Adverse Reaction"],"enrollment":220,"completionDate":"2022-12-30"},{"nctId":"NCT04970667","phase":"PHASE4","title":"Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2018-01-01","conditions":["Emotional Disorder","Neurologic Disorder"],"enrollment":100,"completionDate":"2020-04-30"},{"nctId":"NCT04898270","phase":"PHASE4","title":"Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2019-12-19","conditions":["Schizophrenia; Psychosis","Metabolic Syndrome","Flupentixol","Antipsychotic Agents","Central Nervous System Diseases","Clinical Therapy","Olanzapine","Quetiapine"],"enrollment":30,"completionDate":"2021-04-20"},{"nctId":"NCT02723903","phase":"PHASE1,PHASE2","title":"Hierarchical Treatment Based on Somatization Symptom Checklist","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2015-12","conditions":["Syndrome X"],"enrollment":200,"completionDate":"2021-12"},{"nctId":"NCT03600974","phase":"","title":"A New System for GERD Diagnosis and Treatment","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2019-02-01","conditions":["GERD"],"enrollment":200,"completionDate":"2021-07-01"},{"nctId":"NCT03205228","phase":"PHASE3","title":"Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-07","conditions":["Globus"],"enrollment":40,"completionDate":"2018-07-28"},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":["Schizophrenia","Schizoaffective Disorder"],"enrollment":24,"completionDate":"2019-07"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT00000274","phase":"PHASE2","title":"Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1997-03","conditions":["Cocaine-Related Disorders","Substance-Related Disorders"],"enrollment":60,"completionDate":"1999-05"},{"nctId":"NCT00000266","phase":"PHASE2","title":"Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1994-08","conditions":["Cocaine-Related Disorders"],"enrollment":0,"completionDate":"2001-12"},{"nctId":"NCT00000241","phase":"PHASE2","title":"Flupenthixol Decanoate in Methamphetamine Smoking - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1994-02","conditions":["Substance-Related Disorders"],"enrollment":58,"completionDate":"1996-05"},{"nctId":"NCT00000275","phase":"PHASE2","title":"Cocaine Abuse and ADHD - 10","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1996-11","conditions":["Cocaine-Related Disorders"],"enrollment":16,"completionDate":"1998-03"},{"nctId":"NCT00000349","phase":"PHASE1","title":"Infusion Laboratory: Protocol 5 (Flupenthixol) - 14","status":"UNKNOWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"","conditions":["Cocaine-Related Disorders"],"enrollment":0,"completionDate":""},{"nctId":"NCT02660840","phase":"PHASE1","title":"Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-01","conditions":["Bioequivalence Study in Healthy Subjects"],"enrollment":84,"completionDate":""},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":["Psychotic Disorders","Schizophrenia","Schizoaffective Disorder","Bipolar Disorder","Diabetes Mellitus, Type 2"],"enrollment":725489,"completionDate":"2012-12"},{"nctId":"NCT01164059","phase":"PHASE4","title":"Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia","status":"COMPLETED","sponsor":"University of Bremen","startDate":"2010-02","conditions":["Schizophrenia"],"enrollment":149,"completionDate":"2014-03"},{"nctId":"NCT01851863","phase":"PHASE4","title":"Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2013-05","conditions":["Dyspepsia","Compliance","Depression"],"enrollment":262,"completionDate":"2014-06"},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":["Psychosis Nos/Other"],"enrollment":104,"completionDate":"2015-11"},{"nctId":"NCT02179931","phase":"PHASE1","title":"Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-06","conditions":["Healthy Men and Women"],"enrollment":30,"completionDate":""},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":["Schizophrenia"],"enrollment":100,"completionDate":"2012-12"},{"nctId":"NCT00841230","phase":"PHASE4","title":"Deanxit and Rivotril in Tinnitus Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2009-02","conditions":["Tinnitus"],"enrollment":50,"completionDate":"2009-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003477","UNII":"21HMQ851IS","CHEBI":"CHEBI:5121","INN_ID":"1745","RXNORM":"235742","UMLSCUI":"C0016367","ChEMBL_ID":"CHEMBL54661","KEGG_DRUG":"D01044","DRUGBANK_ID":"DB00875","PUBCHEM_CID":"5281881","SNOMEDCT_US":"387567006","IUPHAR_LIGAND_ID":"948","SECONDARY_CAS_RN":"2413-38-9","MESH_DESCRIPTOR_UI":"D005475"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"34.2 hours","clearance":"4.14 mL/min/kg","bioavailability":"50%"},"publicationCount":446,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AF01","allCodes":["N05AF01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 17","pmid":"41249411","title":"Evaluating the ciprofloxacin potentiation efficacy of repurposed drug flupentixol through efflux pump inhibition of pathogenic bacteria.","journal":"Scientific reports"},{"date":"2025","pmid":"41210421","title":"Bilateral temporomandibular joint dislocation secondary to acute dystonia induced by antipsychotic depot injection: a case report.","journal":"AME case reports"},{"date":"2025 Dec","pmid":"41063663","title":"Osmotic Demyelination Syndrome in a Patient With Schizophrenia: A Case Report.","journal":"Neuropsychopharmacology reports"},{"date":"2025 Aug 24","pmid":"41011127","title":"Use of TLC and Computational Methods to Determine Lipophilicity Parameters of Selected Neuroleptics: Comparison of Experimental and Theoretical Studies.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2025 Sep 12","pmid":"40936465","title":"Correlations between receptor occupancy change and mental state in patients using long-acting injectable antipsychotics: MIDILIA pilot study.","journal":"BJPsych open"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Fluanxol (Flupentixol) is a small molecule high-risk QT prolonging agent that targets the histamine H1 receptor. It is used to treat schizophrenia, but its commercial status is unknown. The drug has a half-life of 34.2 hours and bioavailability of 50%. Key safety considerations include its potential to prolong the QT interval, a risk factor for serious cardiac arrhythmias. Its approval status and generic availability are also unclear.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1964-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}